← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
88%Confidence
0Views
FDASource
2026-04-14Date

Summary

Dry eye relief products from K.C. Pharmaceuticals also show sterility assurance failures, indicating comprehensive manufacturing deficiencies. This affects multiple retail brands including Rite Aid and could damage consumer trust in store-brand ophthalmic products.

Actionable: Coordinate with affected retailers to implement immediate recall procedures for all K.C. Pharmaceuticals eye care products.

AI Confidence: 88%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productDry Eye Relief Eye Drops, (glycerin 0.2%, hypromellose 0.2% and polyethylene glycol 400 1%) 0.5 FL OZ (15 mL) bottles; a) GERI CARE, Distributed by:

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now